Keyphrases
Postmenopausal Women
100%
Aromatase Inhibitors
100%
Adjuvant Therapy
100%
Ovarian Suppression
100%
Women with Breast Cancer
100%
Exemestane
40%
Early Breast Cancer
40%
Estrogen Receptor-positive Breast Cancer
40%
Disease-free Survival
40%
Improved Outcomes
20%
Breast Cancer
20%
Phase III Clinical Trial
20%
Hormone Receptor-positive
20%
2-phase
20%
Estrogen Receptor-positive
20%
Neoadjuvant Endocrine Therapy
20%
Adjuvant Endocrine Therapy
20%
Micrometastatic Disease
20%
Cancer Adjuvant
20%
Prevent Recurrence
20%
Medicine and Dentistry
Breast Cancer
100%
Aromatase Inhibitor
100%
Premenopause
100%
Adjuvant Therapy
100%
Tamoxifen
100%
Recurrent Disease
50%
Disease Free Survival
50%
Estrogen Receptor Positive Breast Cancer
50%
Exemestane
50%
Clinical Trial
25%
Hormone Therapy
25%
Postmenopause
25%
Adjuvant Endocrine Therapy
25%
Estrogen Receptor
25%
Hormone Receptor
25%
Diseases
25%
Pharmacology, Toxicology and Pharmaceutical Science
Tamoxifen
100%
Breast Cancer
100%
Aromatase Inhibitor
100%
Exemestane
50%
Recurrent Disease
50%
Estrogen Receptor Positive Breast Cancer
50%
Disease Free Survival
50%
Clinical Trial
25%
Estrogen Receptor
25%
Endocrine Therapy
25%
Hormone Cancer Therapy
25%
Hormone Receptor
25%
Diseases
25%